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OBJECTIVE — Todeterminetherateofadherencetopostpartumglycemictestinginwomen
with gestational diabetes mellitus (GDM) and the performance of fasting plasma glucose (FPG)
versus the 75-g oral glucose tolerance test (OGTT) in detecting postpartum glucose intolerance.
RESEARCH DESIGN AND METHODS — The study was a retrospective cohort of
1,006 women with GDM attending a pregnancy diabetes clinic.
RESULTS — Postpartum screening was completed in 438 (48%) women. Women nonadher-
ent to testing had higher parity (1.10 vs. 0.87) and were less likely to require insulin for
management of their GDM. Among women who were tested, 89 (21%) had an abnormal result,
only 25 (28%) of whom were identiﬁed by FPG. Factors associated with abnormal postpartum
diabetes screening include non-Caucasian ethnicity, previous GDM, higher A1C, and OGTT
values during pregnancy and treatment with insulin.
CONCLUSIONS — The rate of postpartum diabetes screening is low, and FPG lacks sensi-
tivity as a screening test in comparison with OGTT.
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G
estational diabetes mellitus (GDM)
strongly predicts future develop-
ment of type 2 diabetes (1), and ab-
normal glucose tolerance can persist
postpartum leading to impaired fasting
glucose(IFG),impairedglucosetolerance
(IGT), and type 2 diabetes (2). Compared
with an oral glucose tolerance test
(OGTT), fasting plasma glucose (FPG)
has greater reproducibility but may lack
sensitivity to identify women with IGT or
type2diabetes(3–5).Themainstudyob-
jectives were to assess adherence with
postpartum testing, to identify factors as-
sociated with nonadherence, and to com-
pare the sensitivity of FPG versus a 75-g
OGTT in detecting postpartum glucose
intolerance.
RESEARCH DESIGN AND
METHODS— A retrospective cohort
study was conducted in women with
GDM and IGT of pregnancy seen at the
Grey Nuns Community Hospital Gesta-
tional Diabetes Clinic, Edmonton, Al-
berta, from April 1999 to March 2006.
ThestudywasapprovedbytheUniversity
of Alberta Health Research Ethics Board.
Women were referred to the clinic based
onscreeningat24–32weeks’gestationas
per existing Canadian guidelines (6). A
1-hplasmaglucose(PG)measurementaf-
ter a 50-g glucose load of 10.3 mmol/l
was considered as diagnostic of GDM,
and 7.8 mmol/l was considered normal
(7). An indeterminate value (7.8–10.2
mmol/l) prompted a 75-g OGTT, with
two or more abnormal values (FPG 5.3
mmol/l, 1-h PG 10.6 mmol/l, and 2-h
PG 8.9 mmol/l) (7) diagnostic of GDM,
and a single elevated value was diagnostic
of IGT of pregnancy.
All consecutive women with GDM or
IGTofpregnancywereincluded.Women
withpreexistinghyperglycemia(type1or
type 2 diabetes, IFG, or IGT) and those
whodidnotundergoaroutinegestational
diabetic screen were excluded. Data were
obtained from patient medical records,
including age, parity, ethnicity (Cauca-
sian versus non-Caucasian), self-reported
prior history of GDM and family history
of diabetes (ﬁrst- or second-degree rela-
tives), self-reported prepregnancy weight
and BMI, initial A1C value, insulin use
during pregnancy (yes versus no), and
postpartum diabetes screening values
(FPG or 75-g OGTT). Diabetes was de-
ﬁnedasFPG7mmol/lor2-hPG11.1
mmol/l, IFG as FPG of 6.1–6.9 mmol/l,
and IGT as 2-h PG of 7.8–11.1 mmol/l
(6).Topromoteadherencetopostpartum
testing,requisitionsweregiventowomen
at 35–40 weeks’ gestation for testing be-
tween6weeksand6monthspostpartum,
and they received a phone reminder if
testing was not completed by 6 months.
The data were tabulated in Microsoft
Excel software (Microsoft, Redmond,
WA). The 
2 test for categorical or t test
for continuous variables and logistic re-
gression with calculation of odds ratio for
signiﬁcantvalueswereusedtoanalyzefor
differences between the women who un-
derwent postpartum testing and those
who did not and for the variables associ-
ated with postpartum hyperglycemia.
RESULTS— A total of 1,006 women
wereseenattheclinicbetweenApril1999
and March 2006, of whom 97 were ex-
cluded. Table 1 presents the characteris-
tics of the 909 study participants. There
were 438 (48.2%) women who under-
went postpartum testing, in whom 21
only completed an FPG. Women nonad-
herenttotestinghadahigherparity(odds
ratio[OR]1.39,P0.02,nulliparityver-
sus higher parity) and were less likely to
have used insulin (OR 0.65, P  0.003)
during pregnancy than women who ad-
heredtotestingbutdidnototherwisedif-
fer (Table 1). A total of 14 women who
had postpartum testing were diagnosed
with type 2 diabetes, while 15 had IFG,
57hadIGT,and3hadboth.TheFPGand
OGTT were abnormal in 25 (5.7%) and
89(21.3%)women,respectively,whereas
only ﬁve women had both abnormal FPG
and 2-h PG values. If only an FPG was
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tum hyperglycemia would have been
missed.
Among the characteristics examined,
postpartum hyperglycemia was signiﬁ-
cantly associated with non-Caucasian
ethnicity (OR 3.72, P  0.001), previous
GDM (OR 2.07, P  0.01), higher preg-
nancy OGTT values (fasting 5.20  0.73
vs.4.960.63mmol/l,P0.01;1-hPG
11.74  1.31 vs. 10.86  1.45 mmol/l,
P0.001;2-hPG9.431.71vs.8.73
1.51, P  0.003), higher A1C value
(5.750.61vs.5.500.49,P0.001),
and the use of insulin during pregnancy
(OR 2.53, P  0.002).
CONCLUSIONS — Despite attempts
to improve adherence, 50% of our co-
hort underwent postpartum testing for
glucose intolerance, and only higher par-
ity and lack of insulin use were signiﬁ-
cantly associated with nonadherence to
testing.Lackofchildcareasreﬂectedbya
higher parity may hinder testing, as has
been previously reported (8). Insulin use
in pregnancy may lead to a greater per-
ceived risk of postpartum hyperglycemia
among patients, but its role in promoting
adherencetopostpartumtestinghasbeen
discrepant in the literature (8,9), the rea-
sonforwhichisunclear.Thecontribution
ofsocioeconomicstatustogeneralnonad-
herence to medical recommendation has
beenpreviouslyreported(10)butwasnot
examined in this study. Possible contrib-
utors to the relatively low adherence rate
include conﬂicting guidelines from the
Canadian Diabetes Association versus the
SocietyofObstetricsandGynecologistsof
Canada (11,12) and ambiguity as to
which provider should arrange for test-
ing (13), while a lack of medical re-
sources unlikely contributes given a
previously reported high adherence
with postpartum cervical screening
(14). Although phone reminders were
used, a case manager and/or in-person
postpartum follow-up may further im-
prove adherence (8).
FPG is an inadequate screening tool
to detect postpartum hyperglycemia,
since the majority of cases will be missed.
The lowering of FPG to 5.6 mmol/l has
been suggested to improve diagnostic
sensitivity in IFG, since this value more
accurately reﬂects the increased risk for
development of future diabetes or cardio-
vascular disease (15). However, even if a
FPG cutoff of 5.6 mmol/l was applied to
thecohort,56%ofcasesofhyperglycemia
would be missed without completion of
the 75-g OGTT.
Pooradherencetopostpartumtesting
precludes early detection and timely in-
tervention among these at-risk women.
Given the rising incidence of postgesta-
tional hyperglycemia (1) and a lack of re-
liablepredictorstoidentifynonadherence
to postpartum testing, universal screen-
ing with an OGTT should be applied to
this high-risk population.
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